$VIGONVITA-B(02630.HK)definitely go up
Overview
VIGONVITA-B (2630)
Vigonvita Life Sciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule drugs for neurops...
- Open
- 72.800
- High
- 73.650
- Low
- 69.000
- Prev. Close
- 72.650
- Volume
- 226.20K
- Turnover
- 16.46M
- Avg Price
- 72.746
- Bid/Ask Ratio
- -90.91%
- Amplitude
- 6.40%
- 52wk High
- 134.900
- Volume Ratio
- 2.90
- Turnover Ratio
- 0.14%
- 52wk Low
- 52.000
- HK Mkt Cap
- 12.09B
- Market CapHKD
- 12.14B
- P/ETTM
- Loss
- P/EDynamic
- Loss
- P/EStatic
- --
- EPSTTM
- -2.11
- EPSDynamic
- -1.69
- EPSStatic
- --
- BVPS
- 1.48
- P/B
- 49.16
- HK Shares
- 165.97M
- Dividend YieldTTM
- --
- DividendTTM
- --
- Shares
- 166.67M
- Min lot size
- 200
- Currency
- HKD
Daily Events
- Nov, 16
TPN171's Hong Kong and Macau filings being accepted, alongside repeated share-repurchase disclosures, failed to absorb profit-taking, and the stock traced a deep V today: it fell 5.0% to HK$69.00 by 10:22, rebounded to HK$73.00 at 13:51 before easing to close at HK$71.90, down about 1.0% on 226,600 shares worth HK$16.48 million. Operations are improving off a low base, with Q2 2026 revenue of HK$76.1 million, up 736.58% year on year, while the net loss narrowed 25.63% to HK$70.5 million, leaving net margin at -92.64% and EPS at -HK$0.4216. The price sits 46% below its 52-week high of HK$134.90 and 13.33% lower year to date, beneath the MA20 of HK$75.62 and MA60 of HK$82.28, with PB at 49.16 times against a HK$12.14 billion market value. Though last week's 21.39% rebound shows buybacks and filing progress can still move the tape quickly.
- Nov, 13
Vigonvita (2630.HK) reversed early gains even after TPN171 NDAs were accepted in Hong Kong and Macau, opening at HK$75.50, the session high, then sliding to HK$70.70 by 14:31 BJ and settling near HK$72.05 with the latest print at HK$72.75, about 3% below the prior HK$75.00 close on roughly 127,000 shares. The move extends a choppy stretch: the stock fell 10% on 6 November and 13% on 9 November despite near-daily buyback disclosures, leaving the week down 12.96%, while 10 November brought a 12% rebound. Q2 2026 revenue reached HK$76.1 million, up 736.58% year on year, and the net loss narrowed 25.63% to HK$70.5 million, yet the net margin stayed at -92.64% with a loss of HK$0.4216 per share; PB is 49.12x against a negative PE. The shares sit below the MA20 of HK$75.94 and MA60 of HK$82.50, down 13.44% year to date and 46.07% under the 22 February high of HK$134.90, though still 42.65% above the HK$51.00 low.
- Nov, 11
Vigonvita (2630.HK) opened at HK$70.0 and ground higher through the session to HK$74.7 by 15:58 BJ, then gave back part of the gain to close at HK$73.2, up 4.13%, on only 22,200 shares and HK$1.65 million of turnover. The move follows a 12.96% weekly slide in which repeated share-buyback disclosures failed to stop the decline, so the rebound looks more like a technical repair after the drop than a return of real money. Fundamentals cut both ways: Q2 2026 revenue reached HK$76.1 million, up 736.58% year on year, and the net loss narrowed 25.63% to HK$70.5 million, yet net margin is still -92.64%, loss per share -HK$0.4216, ROE -113.81%, with a 49.49x price-to-book against a negative P/E. At HK$73.2 the stock sits 45.74% below its 52-week high of HK$134.9 and down 12.91% year to date, under both the MA20 of HK$76.64 and MA60 of HK$82.89. Though a turnover rate of just 0.01% means the thin float can exaggerate single-day swings.
- Nov, 10
Vigonvita-B (2630.HK) reversed an early dip to close up 17.2% at HK$70.15 versus the prior close of HK$59.85, on 956,200 shares and HK$58.55 million turnover, as all pre-IPO investors including the controlling shareholder voluntarily extended their lock-up period, extending a buyback run of about 460,200 shares worth roughly HK$36.12 million between November 2 and 6. The session traced a low-open, high-close pattern: a morning low of HK$60.25 at 09:30, then acceleration through the afternoon to an intraday peak of HK$70.35 at 15:46, following a 12.96% weekly decline. Q2 2026 revenue reached HK$76.1 million, up 736.58% year on year, while the net loss narrowed 25.63% to HK$70.5 million at a -92.64% net margin. Even after today's move the price stays below the MA20 of HK$76.9 and MA60 of HK$83.18, down 16.54% year to date and 48% below the 52-week high of HK$134.9. Though a 47.43x price-to-book and negative PE keep the stock sensitive to delivery on that revenue growth.
- Nov, 9
A second straight session of heavy selling: after sliding 12.96% last week, the stock dropped 13.5% to HK$59.85, tracing a spike-and-fade pattern that stalled at HK$69.20 in the morning session, gave back all morning gains, and ground down to HK$60.00 in the afternoon, closing near the session low. Volume was thin at 87,800 shares and HK$5.53 million turnover, a 0.05% turnover rate, with poor liquidity amplifying the move. Fundamentals cut against the tape: Q2 2026 revenue reached HK$76.1 million, up 736.58% year on year, while the net loss narrowed 25.63% to HK$70.5 million and net margin stayed at -92.64%. On price position, the shares sit 55.63% below the 52-week high of HK$134.90, down 28.79% year to date, below both MA20 of HK$77.46 and MA60 of HK$83.56, and only 17% above the HK$51 low. Though buybacks ran daily from November 2 to 6, including 133,600 shares for HK$10.38 million on November 6, and pre-IPO investors including the controlling shareholder voluntarily extended lock-ups, offering some support.
News
PUBT · Vigonvita Life Sciences Files HKEX Return Disclosing Share Buyback
Weekly Review · Weekly Recap | VIGONVITA-B +21.39%, drug filing accepted in HK and Macau
PUBT · Vigonvita Life Sciences Files HKEX Next Day Disclosure Return Announcing Share Repurchase
Market Movers · Vigonvita falls 6% in Hong Kong trading
Tip Ranks · Vigonvita TPN171 NDAs Accepted in Hong Kong and Macau
PUBT · Vigonvita Life Sciences corrects fund manager disclosures in interim report
